Elsevier

Pharmacological Research

Volume 50, Issue 4, October 2004, Pages 385-396
Pharmacological Research

The current status of Alzheimer’s disease genetics: what do we tell the patients?

https://doi.org/10.1016/j.phrs.2003.11.018Get rights and content

Abstract

Alzheimer’s disease (AD) is a genetically complex and heterogeneous disorder. Fully penetrant (causal) mutations leading to predominantly early-onset familial AD have been identified in three genes (APP, PSEN1, PSEN2), while for the more common late-onset form of the disease, only one partially penetrant genetic risk factor (APOE) has been established to date. Several lines of evidence suggest that additional susceptibility genes exist for both early- and late-onset AD, however, none of the more than three dozen putative AD loci proposed to date have been consistently replicated in follow-up analyses. Novel AD genes will not only provide valuable clues for the development of novel therapeutic approaches, but will also allow the development of new genetic risk profiling strategies that are an essential prerequisite for early prediction/prevention of this devastating disease. This review focuses on the analytic tools used to identify genes in complex diseases, and then provides a summary of recent linkage and association findings indicating the existence of novel late-onset AD genes on several chromosomes.

Introduction

Over the past two decades, genetic studies have been remarkably successful in the identification of fully penetrant, causal mutations in Mendelian disease genes. However, some of these genes only account for an uncommon subset of generally more widespread disorders such as breast cancer, colon cancer, diabetes and early-onset Alzheimer’s disease. These diseases share several characteristics that classify them as genetically complex and heterogenous. They are complex because there is no single (or simple) mode of inheritance that accounts for their heritability; they are heterogeneous because mutations and polymorphisms in multiple genes interact with one another and with non-genetic factors (Fig. 1). Thus, one plausible explanation for the disappointing achievement of positional cloning strategies in more common and genetically complex diseases is that the underlying and predisposing variants (or “susceptibility genes”) exert only small to modest effects with weak genotype–phenotype correlations [1]. Nonetheless, the magnitude of their attributable risk may be quite large because they are relatively frequent in the population, rendering them a significant public health issue [2].

Alzheimer’s disease (AD), the most common form of age-related dementia, is characterized by progressive and insidious neurodegeneration of the central nervous system leading to a gradual decline of cognitive function and dementia. The key neuropathological features of AD are abundant amounts of neurofibrillary tangles and β-amyloid (Aβ) deposited in the form of senile plaques. While our understanding of the disease pathophysiology still remains fragmentary, it is now widely accepted that genes play an essential role in predisposing to onset and in modifying the progression of the disease. Specifically, disease inheritance shows an age-related dichotomy in which rare but highly penetrant mutations transmitted in an autosomal dominant manner have been thus far responsible for early (≤60 years) onset familial forms of AD, while common polymorphisms with low penetrance appear to have their greatest effect on the more frequent, later onset forms of the disease (LOAD; [3]). Several additional factors aggravate the identification and consistent replication of bona fide AD genes—or other complex disease genes—across studies and populations (such as unknown phenocopy rates, sampling issues, population stratification, etc.). These difficulties are evidenced by the fact that of the almost 100 candidate AD genes analyzed in the literature to date, only four have been proven to either play a direct role in AD pathogenesis (APP, PSEN1, PSEN2) or to significantly increase disease susceptibility in almost every study population analyzed worldwide (i.e. APOE; Table 1).

Despite the complexities of AD genetics, tremendous progress has been made over the past two decades. The knowledge gained from genetic studies of AD was and remains the essential prerequisite for our current understanding of the etiological and pathophysiological mechanisms leading to neurodegeneration in AD as well as for the development of novel strategies for the treatment and prevention of this disease.

Section snippets

Analysis of genetic linkage

Linkage analysis measures the vertical coseggregation of specific marker alleles (e.g. those of microsatellites) and disease phenotype within individual families. This can be done either by formulating specific inheritance models (“parametric analyses”), or model-free (“non-parametric”). If the model is correctly specified, parametric methods are usually more powerful as they permit the use of affected and unaffected individuals alike [4]. However, because one characteristic of complex diseases

Early-onset Alzheimer’s disease

Only small fraction of all AD cases (<5–10%) can be explained by early-onset familial AD [3]. In 1987, initial results showed linkage to the long arm of chromosome 21 encompassing a region that harbored the gene encoding the amyloid precursor protein (APP; gene: APP), a compelling candidate gene for AD [6]. This chromosomal area overlaps with the obligate region for Down’s syndrome, a disease where affected individuals almost invariably develop AD after a certain age. In 1991, the first APP

Late-onset Alzheimer’s disease

As outlined above and in Fig. 1, late-onset Alzheimer’s is characterized by a considerably more multifaceted and interwoven pattern of genetic and non-genetic factors that is only poorly understood. Adding to these complexities are methodological difficulties inherent to common diseases in general and late-onset diseases like AD in particular. These and other characteristics largely reduce the power to detect new loci in reasonably sized samples and make the identification and independent

Clinical implications

How does this continuously increasing knowledge about the genetic make-up of AD translate into clinical practice or, to return to the subtitle of this review: what do we tell the patients? The answer to this question is much less complex than the disease itself and, unfortunately, must read: not much, yet. Predictive genetic testing is a very delicate process in any disease, as it deeply invades the privacy of the individual and his or her family members. If a preventive treatment or cure is

Conclusion

Despite the great progress in the field of AD genetics that has led to the discovery and confirmation of three autosomal-dominant early-onset genes and a late-onset risk-factor, a number of other additional major AD loci are predicted to exist. The hunt for these putative AD genes is aggravated by several factors that generally complicate the identification of complex disease genes: locus and/or allelic heterogeneity; only minor to modest effect size of any given variant; unknown—and difficult

References (83)

  • M.A. Wollmer et al.

    ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease

    Neurobiol. Aging

    (2003)
  • D.J. Selkoe

    Clearing the brain’s amyloid cobwebs

    Neuron

    (2001)
  • G. Ait-Ghezala et al.

    Confirmation of association between D10S583 and Alzheimer’s disease in a case-control sample

    Neurosci. Lett.

    (2002)
  • D. Edbauer et al.

    Insulin-degrading enzyme rapidly removes the β-amyloid precursor protein intracellular domain (AICD)

    J. Biol. Chem.

    (2002)
  • M. Boussaha et al.

    Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer’s disease

    Neurosci. Lett.

    (2002)
  • S.D. Edland et al.

    Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer’s disease: evidence of effect modification by apolipoprotein E (APOE)

    Neurosci. Lett.

    (2003)
  • G.S. Zubenko et al.

    A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution

    Genomics

    (1998)
  • M. Takehashi et al.

    Association of monoamine oxidase A gene polymorphism with Alzheimer’s disease and Lewy body variant

    Neurosci. Lett.

    (2002)
  • L. Emilsson et al.

    Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer’s disease patients

    Neurosci. Lett.

    (2002)
  • H.L. Paulson

    Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations

    Neurol. Clin.

    (2002)
  • R.E. Tanzi et al.

    New frontiers in Alzheimer’s disease genetics

    Neuron

    (2001)
  • N.J. Risch

    Searching for genetic determinants in the new millennium

    Nature

    (2000)
  • N. Risch et al.

    The future of genetic studies of complex human diseases

    Science

    (1996)
  • R.E. Tanzi

    A genetic dichotomy model for the inheritance of Alzheimer’s disease and common age-related disorders

    J. Clin. Invest.

    (1999)
  • E. Lander et al.

    Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results

    Nat. Genet.

    (1995)
  • R.E. Tanzi et al.

    Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus

    Science

    (1987)
  • A. Goate et al.

    Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease

    Nature

    (1991)
  • R. Sherrington et al.

    Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease

    Nature

    (1995)
  • E. Levy-Lahad et al.

    Candidate gene for the chromosome 1 familial Alzheimer’s disease locus

    Science

    (1995)
  • E.I. Rogaev et al.

    Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene

    Nature

    (1995)
  • Ott J. Analysis of human genetic linkage. Baltimore: Johns Hopkins University Press;...
  • R.S. Spielman et al.

    Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)

    Am. J. Hum. Genet.

    (1993)
  • M. Mullan et al.

    A locus for familial early-onset Alzheimer’s disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene

    Nat. Genet.

    (1992)
  • G.D. Schellenberg et al.

    Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14

    Science

    (1992)
  • P. St. George-Hyslop et al.

    Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14

    Nat. Genet.

    (1992)
  • C. Van Broeckhoven et al.

    Mapping of a gene predisposing to early-onset Alzheimer’s disease to chromosome 14q24.3

    Nat. Genet.

    (1992)
  • C. Haass et al.

    The presenilins in Alzheimer’s disease—proteolysis holds the key

    Science

    (1999)
  • D. Blacker et al.

    Results of a high-resolution genome screen of 437 Alzheimer’s disease families

    Hum. Mol. Genet.

    (2003)
  • C.J. Phiel et al.

    GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides

    Nature

    (2003)
  • R. Vassar

    The beta-secretase, BACE: a prime drug target for Alzheimer’s disease

    J. Mol. Neurosci.

    (2001)
  • C.M. Kirschling et al.

    Polymorphism in the BACE gene influences the risk for Alzheimer’s disease

    Neuroreport

    (2003)
  • Cited by (114)

    • The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases

      2022, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      However, the glaringly obvious disadvantage of these models is the absence of Aβ plaques, a classical hallmark of AD neuropathology. This is especially disheartening given the fact that PSEN1 mutations produce an aggressive form of familial AD, with known amyloid deposits and early-onset symptomology in humans (Bertram and Tanzi, 2004). However, this may speak to the limitation of using mice transgenic models which only express a single missense mutation.

    • Molecular aspects of metallothioneins in dementias

      2020, Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2
    • The role of dopaminergic midbrain in Alzheimer's disease: Translating basic science into clinical practice

      2018, Pharmacological Research
      Citation Excerpt :

      Alzheimer's disease (AD), including the genetically inherited form for which exist a family medical history [1,2] is a progressive neurological disorder causing dementia in an increasingly large proportion of the aging worldwide population.

    • Genomic variation in neurons

      2024, Development Growth and Differentiation
    View all citing articles on Scopus
    View full text